tiprankstipranks
Trending News
More News >
BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Australian Market
Advertisement

BCAL Diagnostics Limited (BDX) AI Stock Analysis

Compare
7 Followers

Top Page

AU:BDX

BCAL Diagnostics Limited

(Sydney:BDX)

Rating:45Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
BCAL Diagnostics Limited faces significant challenges with profitability and cash flow, as highlighted by its financial performance. Technical indicators suggest potential bearish trends, while valuation metrics indicate financial difficulties. These factors collectively contribute to a lower overall stock score.

BCAL Diagnostics Limited (BDX) vs. iShares MSCI Australia ETF (EWA)

BCAL Diagnostics Limited Business Overview & Revenue Model

Company DescriptionBCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
How the Company Makes MoneyBCAL Diagnostics Limited generates revenue through the commercialization of its proprietary blood-based diagnostic tests. The company's primary revenue stream comes from selling these diagnostic tests to healthcare providers, clinics, and laboratories. Additionally, BCAL Diagnostics may engage in partnerships or collaborations with other biotech firms and research institutions to further develop and distribute its diagnostic technologies, potentially leading to licensing fees and joint venture earnings. The company may also explore grants or funding from governmental or private institutions to support its research and development efforts.

BCAL Diagnostics Limited Financial Statement Overview

Summary
BCAL Diagnostics Limited is experiencing revenue growth but continues to struggle with profitability and cash flow management. The low leverage provides some financial stability, yet persistent losses and negative cash flows present significant challenges. Strategic improvements are needed to enhance operational efficiency and financial performance.
Income Statement
45
Neutral
The company showed a modest revenue growth of 8.59% from 2023 to 2024, but continues to face significant profitability challenges. The gross profit margin remains positive, but both EBIT and EBITDA margins are negative, indicating operational inefficiencies. The net profit margin is also negative, reflecting ongoing losses.
Balance Sheet
50
Neutral
The balance sheet shows a relatively stable equity position with a debt-to-equity ratio of 0.18, suggesting low leverage. However, the equity ratio of 70.05% indicates a reliance on equity financing. The return on equity is negative due to net losses, highlighting a lack of profitability.
Cash Flow
40
Negative
Cash flows are under pressure with negative operating and free cash flows. The free cash flow growth rate improved slightly but remains negative. The operating cash flow to net income ratio is not favorable, indicating challenges in converting income into cash.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue3.10M2.85M718.67K275.25K442.10K
Gross Profit3.10M2.74M698.06K275.25K434.37K
EBITDA-5.67M-7.72M-4.06M-1.80M-1.03M
Net Income-6.40M-5.06M-3.39M-1.52M-696.36K
Balance Sheet
Total Assets12.27M8.37M10.59M4.13M819.55K
Cash, Cash Equivalents and Short-Term Investments6.47M3.17M9.57M3.41M416.23K
Total Debt1.52M1.06M0.000.00300.00K
Total Liabilities3.68M3.16M950.42K525.60K380.64K
Stockholders Equity8.59M5.21M9.64M3.61M438.92K
Cash Flow
Free Cash Flow-5.67M-6.41M-7.25M-1.21M-665.46K
Operating Cash Flow-4.52M-6.05M-3.22M-1.21M-661.65K
Investing Cash Flow-1.15M3.64M-4.03M-3.85K-3.81K
Financing Cash Flow8.97M13.24K9.41M4.20M805.04K

BCAL Diagnostics Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.07
Price Trends
50DMA
0.07
Positive
100DMA
0.08
Negative
200DMA
0.09
Negative
Market Momentum
MACD
<0.01
Negative
RSI
54.30
Neutral
STOCH
62.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Neutral. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.30 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:BDX.

BCAL Diagnostics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
€4.79B16.30-48.29%2.23%15.31%-8.27%
52
Neutral
AU$50.90M-51.49%80.84%57.59%
47
Neutral
AU$3.42M
55.07%88.20%
45
Neutral
AU$25.25M-104.23%-17.26%
41
Neutral
AU$15.39M-71.10%76.17%
AU$1.48M
45
Neutral
AU$41.86M-39.07%26.07%0.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BDX
BCAL Diagnostics Limited
0.07
-0.05
-41.67%
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.07
0.02
40.00%
AU:WFL
Wellfully Limited
0.01
0.00
0.00%
AU:IBX
Imagion Biosystems Ltd.
0.02
-0.04
-66.67%
AU:IIQ
Inoviq Ltd
0.36
-0.24
-40.00%

BCAL Diagnostics Limited Corporate Events

BCAL Diagnostics Partners with Cancer Care Associates to Boost BREASTEST plus™ Adoption
Jul 2, 2025

BCAL Diagnostics Limited has announced a strategic partnership with Cancer Care Associates to accelerate the adoption of their non-invasive breast cancer diagnostic test, BREASTEST plus™. This partnership is a significant commercial milestone for BCAL, providing a pathway to market adoption and patient access through a leading oncology network in Australia. The collaboration is expected to generate revenue starting in FY2026 and strengthen BCAL’s commercial rollout strategy, potentially leading to broader national and international partnerships. The integration of BREASTEST plus™ into Cancer Care Associates’ offerings will support uptake in various settings and enhance BCAL’s data collection efforts, aiding discussions around reimbursement and regulatory approvals.

BCAL Diagnostics Expands BREASTEST plus Access in Sydney and Melbourne
May 6, 2025

BCAL Diagnostics Limited has announced the expansion of its BREASTEST plus blood test to three additional specialist breast clinics in Sydney and Melbourne, starting mid-May 2025. This expansion aligns with BCAL’s national rollout strategy to improve early breast cancer detection in women with high breast density, a group where traditional mammography often faces challenges. The move is a significant milestone in BCAL’s efforts to provide more women with access to this breakthrough diagnostic tool, enhancing early and accurate diagnosis and potentially improving health outcomes.

BCAL Diagnostics Launches Innovative Breast Cancer Blood Test
Apr 28, 2025

BCAL Diagnostics Limited has launched its first-in-class blood test, BREASTEST plus, which achieved its first revenues in March 2025. This launch represents a significant milestone in breast cancer diagnostics, particularly for women with dense breasts where traditional imaging is less effective. The company is expanding its market access and clinician engagement strategies in Australia, with plans for a national rollout, while also laying the groundwork for US market entry. BCAL continues to strengthen its patent portfolio and maintain a solid financial position with a cash balance of $5 million, focusing on efficient resource deployment to achieve its strategic objectives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025